Madrigal Pharmaceuticals, Inc. MDGL
We take great care to ensure that the data presented and summarized in this overview for MADRIGAL PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MDGL
View all-
Baker Bros. Advisors LP New York, NY2.14MShares$1.13 Billion8.0% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$1.06 Billion12.22% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.91MShares$1.01 Billion31.28% of portfolio
-
Janus Henderson Group PLC London, X01.84MShares$975 Million0.41% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.83MShares$970 Million11.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.81MShares$959 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.43MShares$755 Million0.01% of portfolio
-
State Street Corp Boston, MA658KShares$348 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA446KShares$236 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL412KShares$218 Million0.53% of portfolio
Latest Institutional Activity in MDGL
Top Purchases
Top Sells
About MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Insider Transactions at MDGL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
24,800
-1.36%
|
$13,664,800
$551.76 P/Share
|
|
Dec 10
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,800
+10.47%
|
$372,000
$15.8 P/Share
|
|
Dec 10
2025
|
Rebecca Taub Director |
SELL
Bona fide gift
|
Direct |
5,455
-1.18%
|
-
|
|
Dec 10
2025
|
Rebecca Taub Director |
SELL
Open market or private sale
|
Direct |
18,650
-0.44%
|
$10,276,150
$551.79 P/Share
|
|
Dec 10
2025
|
Rebecca Taub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,650
+3.74%
|
$279,750
$15.8 P/Share
|
|
Dec 04
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
2,400
-1.57%
|
$1,380,000
$575.34 P/Share
|
|
Dec 03
2025
|
William John Sibold President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+24.69%
|
-
|
|
Dec 02
2025
|
Mardi Dier EVP and CFO |
SELL
Open market or private sale
|
Direct |
4,173
-2.21%
|
$2,424,513
$581.45 P/Share
|
|
Dec 02
2025
|
Mardi Dier EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,173
+22.21%
|
$1,047,423
$251.63 P/Share
|
|
Nov 21
2025
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,958
-1.59%
|
$1,086,690
$555.09 P/Share
|
|
Nov 13
2025
|
Richard S Levy Director |
SELL
Open market or private sale
|
Direct |
8,500
-2.36%
|
$4,437,000
$522.33 P/Share
|
|
Nov 13
2025
|
Richard S Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+13.18%
|
$93,500
$11.91 P/Share
|
|
Nov 05
2025
|
Kenneth Bate Director |
SELL
Open market or private sale
|
Direct |
16,575
-15.93%
|
$8,038,875
$485.61 P/Share
|
|
Nov 05
2025
|
Kenneth Bate Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,575
+27.12%
|
$3,265,275
$197.76 P/Share
|
|
Sep 09
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
7,279
-6.63%
|
$3,239,155
$445.63 P/Share
|
|
Aug 21
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
7,616
-3.27%
|
$3,046,400
$400.51 P/Share
|
|
Aug 20
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
59,901
+0.24%
|
$23,001,984
$384.95 P/Share
|
|
Aug 18
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
105,782
+0.31%
|
$38,504,648
$364.61 P/Share
|
|
Aug 18
2025
|
Shannon T Kelley General Counsel |
SELL
Open market or private sale
|
Direct |
1,304
-1.64%
|
$483,784
$371.08 P/Share
|
|
Aug 15
2025
|
Kenneth Bate Director |
SELL
Open market or private sale
|
Direct |
10,000
-22.74%
|
$3,650,000
$365.89 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 45.2K shares |
|---|---|
| Open market or private purchase | 166K shares |
| Exercise of conversion of derivative security | 540K shares |
| Open market or private sale | 462K shares |
|---|---|
| Bona fide gift | 5.46K shares |